LYMPHANGIOGENESIS AND CANCER METASTASIS

Size: px
Start display at page:

Download "LYMPHANGIOGENESIS AND CANCER METASTASIS"

Transcription

1 LYMPHANGIOGENESIS AND CANCER METASTASIS Steven A. Stacker*, Marc G. Achen*, Lotta Jussila, Megan E. Baldwin* and Kari Alitalo Lymphatic vessels are important for the spread of solid tumours, but the mechanisms that underlie lymphatic spread and the role of lymphangiogenesis (the growth of lymphatics) in tumour metastasis has been less clear. This article reviews recent experimental and clinico-pathological data indicating that growth factors that stimulate lymphangiogenesis in tumours are associated with an enhanced metastatic process. LYMPHATIC VESSELS The system of thin-walled, lowpressure vessels that collects fluid, proteins and cells that are released by the blood vessels into the interstitial spaces of tissues. METASTASIS The spread of malignant cells from the original site of the tumour. Spread occurs to such sites as the draining lymph nodes or to distant sites typically the lung, liver or bone marrow in the case of solid tumours (for example, carcinomas tumours of epithelial origin). *Ludwig Institute for Cancer Research, Post Office Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia. Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, The Haartman Institute and Biomedicum Helsinki, P.O.Box 63 (Haartmaninkatu 8), University of Helsinki, Finland. Contributed equally to the review. Correspondence to K. A. doi: /nrc863 METASTASIS Millions of people die every year from the metastatic spread of cancer that occurs via the blood vessels (haematogenous spread), LYMPHATIC VESSELS (lymphogenous spread) or directly into tissues and body cavities. Although the biochemical mechanisms are not well understood, it is thought that the metastatic spread of a tumour is not a random process. Distinct patterns of METASTASIS can be discerned in different tumour types 1.A common pattern for carcinomas is that regional LYMPH NODES are the first sites to develop metastases, either draining via pre-existing afferent lymphatic vessels and/or via newly formed lymphatic capillaries. This pattern of metastasis is central to the usefulness of sentinel lymphadenectomy as a surgical technique 2,3. However, not all tumours initially metastasize to the regional lymph nodes. The mechanisms that determine whether regional lymph nodes or other sites first develop metastases remain poorly understood. In fact, most disseminated tumour cells have a limited lifespan and only a few develop into detectable micrometastases 3,4. Nevertheless, the ability to identify occult tumour cells, as well as prevent their growth and spread, would be of clinical significance. ANGIOGENESIS and lymphangiogenesis provide new vessels that malignant cells can use to escape the confines of the primary tumour. Nevertheless, existing vessels already provide a mechanism of escape, and therefore the relative importance of pre-existing versus new vessels is still to be determined 5. Studies using various inhibitors and other approaches have shown that angiogenesis is important for solid tumour growth 6 10 and, presumably, also in haematogenous metastasis 11. However, little is known about the role of tumour lymphangiogenesis in metastasis and whether this process is important for spread via the lymphatics 12,13. Much of the difficulty in analysing lymphatics is due to the lack of lymphatic-specific markers that could be used to discriminate between lymphatics and blood vessels 14. However, recent experimental and clinical data that employ lymphangiogenic factors and novel lymphatic markers indicate that lymphangiogenic factors influence the spread of tumours. Molecular mediators of lymphangiogenesis The discovery of molecules that promote lymphatic vessel growth and allow the identification of lymphatics has brought a new awareness of the process of lymphangiogenesis The first lymphangiogenic growth factor discovered vascular endothelial growth factor-c (VEGFC) (FIG. 1) has a mature form that consists of the VEGF homology domain (VHD), which contains receptor-binding sites and is 30% identical in amino-acid sequence to VEGF 165 (REFS 22,23). VEGFC is synthesized as a preproprotein, and several forms are generated, by means of stepwise proteolytic processing, that have sequentially increased affinity for VEGFR2 and VEGFR3 (REF. 24) cell-surface-receptor tyrosine kinases that are predominantly expressed on bloodvascular and lymphatic ENDOTHELIA, respectively 25 (FIG. 2). Like VEGF, VEGFC stimulates the migration of endothelial cells and induces vascular permeability and endothelial-cell proliferation, but at higher concentrations than are required for VEGF 22,24. These signals for endothelial cells are probably mediated by means of NATURE REVIEWS CANCER VOLUME 2 AUGUST

2 Growth factors VEGFC (full length) N N N N N Sig VEGFD (full length) VEGF VEGFR2 Sig Ig1 Ig2 N-Pro VHD C-Pro Sig N-Pro VHD C-Pro Sig VHD Hep Receptors VEGFR3 Sig Ig1 Ig2 C Ig3 Ig4 Ig5 Ig6 Ig7 TM C C TK1 TK2 Ig3 Ig4 Ig S S 5 Ig6 Ig7 TM TK1 KI TK2 Figure 1 The protein structure of growth factors and receptors associated with lymphangiogenesis. Two members of the vascular endothelial growth factor (VEGF) family (VEGFC and VEGFD) are implicated in lymphangiogenesis VEGF is shown for comparison. These are secreted homodimeric polypeptides that contain a hydrophobic amino-terminal signal sequence for protein secretion (Sig). All VEGF family members contain a central region that is termed the VEGF homology domain (VHD) and contains a cysteine-knot motif, a structural feature of each subunit that consists of three intra-subunit disulphide bonds forming the shape of a knot. A subfamily of these growth factors contains VEGFC and VEGFD, defined by their ability to bind VEGFR3 and the presence of amino- and carboxy-terminal propeptides (N-Pro and C-Pro). The receptors for VEGFC and VEGFD are VEGFR2 and VEGFR3, both of which can be expressed on lymphatic endothelial cells. These receptors are closely related in structure, consisting of an extracellular domain with seven immunoglobulin-like domains (Ig), a transmembrane domain (TM), a split tyrosine kinase domain (TK) with a kinase insert sequence (KI) and a cytoplasmic tail (CT) at the carboxyl terminus. The fifth Ig-like domain of VEGFR3 is proteolytically processed and the subunits are held together by a disulphide bond (-S-S-). Recent studies have revealed that signalling by VEGFR3 alone is sufficient to induce lymphangiogenesis 20. Some forms of the angiogenic factor VEGF contain a carboxy-terminal heparin-binding domain (Hep). VEGF binds VEGFR1 (not shown here) and VEGFR2, but not VEGFR3. VEGFR2 in blood-vascular-endothelial cells and generally by VEGFR3 (also known as FLT4) in lymphatic endothelial cells, although lymphatic endothelium KI CT C CT C also expresses VEGFR2, which might contribute to signalling for mitogenesis. Unlike VEGF, the expression of VEGFC does not seem to be regulated by hypoxia 26, but is increased in response to proinflammatory cytokines, indicating a role in inflammatory responses 27. The pattern of Vegfc expression in embryos indicates that it has a role in the development of the lymphatic vessels, since a paracrine expression pattern is seen between Vegfc and Vegfr3 at sites in which the first lymphatic sprouts occur 28. In addition, deletion of the Veg fc gene results in embryonic lethality because of failure of lymphaticvessel development (Marika Karkkainen, personal communication). VEGFC can regulate physiological and pathological blood-vessel growth in vivo. It is able to stimulate angiogenesis in the mouse cornea and in limb ischaemia 29,30. In addition, VEGFC has been shown to regulate the growth of lymphatic vessels in various experimental models. Overexpression of VEGFC in skin keratinocytes leads to dermal lymphatic-vessel hyperplasia 16. Signalling by means of VEGFR3 alone was shown to be sufficient for the hyperplasia, as transgenic mice that overexpress a mutant form of VEGFC, which has lost its capacity to bind VEGFR2 and only binds and activates VEGFR3 (VEGFC156S), was able to induce a similar phenotype 20. VEGFC was also studied in the mature avian chorioallantoic membrane (CAM), which contains lymphatic vessels that are located mainly around arterioles and veins 15. In this assay, VEGFC acts as a highly specific lymphangiogenic factor. However, when VEGFC is applied to the early CAM, in which the lymphatics have not yet developed, it promotes angiogenesis 29. The angiogenic versus lymphangiogenic responses to VEGFC might depend on the degree of proteolytic processing of its precursor, and on the expression of its receptors in the blood versus lymphatic endothelial cells of the target tissue. VEGFC also has synergistic effects LYMPH NODE A collection of lymphoid cells which occurs along the course of the lymphatics and serves to filter lymph (the fluid of the lymphatics) for antigen presentation and immune-cell proliferation. The lymph node is frequently the initial site to which tumours spread and is therefore an important diagnostic indicator. ANGIOGENESIS The proliferation of new blood vessels from pre-existing ones. ENDOTHELIUM The group of cells that line the inner surface of both the blood and lymphatic vessels. Endothelial cells can express specialized receptors that allow interaction with cells of the immune system that are present in the blood and lymph. Summary Tumour metastasis to regional lymph nodes is a crucial step in the progression of cancer. Detection of tumour cells in the lymph nodes is an indication of the spread of the tumour, and is used clinically as a prognostic tool and a guide to therapy. However, the molecular mechanisms that control the spread of cancer to the lymph nodes were unknown until recently. The proliferation of new lymphatic vessels (lymphangiogenesis) is controlled, in part, by members of the vascular endothelial growth factor (VEGF) family namely, VEGFC and VEGFD and their cognate receptor on lymphatic endothelium, VEGFR3. These secreted growth factors are synthesized as propeptides that are activated by proteolysis to form high-affinity ligands that activate VEGFR3 and stimulate lymphangiogenesis. The recent identification of molecular markers to discriminate between lymphatic endothelium and blood-vessel endothelium has enabled the study of lymphatic vessel formation in experimental models and in human tumours. Experimental studies with VEGFC and VEGFD have shown that they can induce tumour lymphangiogenesis and direct metastasis to the lymphatic vessels and lymph nodes. By contrast, angiogenic factors such as VEGF act to enhance the growth of tumours by promoting a more extensive blood-vessel supply. The published patterns of expression of lymphangiogenic factors in human tumours, in general, support the hypothesis that these factors promote the lymphatic spread of human tumours. The inhibition of tumour lymphangiogenesis, using inhibitory agents that are directed to VEGFC, VEGFD or its receptor VEGFR3 (for example, monoclonal antibodies, receptor bodies or tyrosine kinase inhibitors), could be useful for anti-metastatic approaches to the treatment of human cancer. 574 AUGUST 2002 VOLUME 2

3 REVIEWS Embryonic Pathological Adult Stromal cell Macrophages Stromal cell Heart Lung Skin Tumour cell Supporting cells surrounding vessels Macrophages Unprocessed VEGFC/D Proteolytic processing Angiogenesis VEGFR2 Lymphangiogenesis VEGFR2 VEGFR3 Figure 2 Mode of action of lymphangiogenic growth factors. The lymphangiogenic growth factors vascular endothelial growth factor-c (VEGFC) and VEGFD are produced by a range of cells and tissues during embryogenesis, adult life and certain pathologies, including cancer. The full-length growth factors are processed by as yet uncharacterized proteases that cleave the amino- and carboxy-terminal propeptides (light blue and red L-shapes, respectively) from the VEGF homology domain (VHD) to generate a mature form that consists of dimers of the VHD (purple oval) that bind the receptors VEGFR2 and VEGFR3 with high affinity. In the case of VEGFD, the mature form has a 290-fold and 40-fold greater affinity for VEGFR2 and VEGFR3, respectively, than the unprocessed form33. Activation of VEGFR3 induces lymphangiogenesis, whereas activation of VEGFR2 is thought to drive angiogenesis. with VEGF during the induction of angiogenesis, and this effect is more prominent in cells that express both of its receptors31. The second lymphangiogenic growth factor to be reported VEGFD (also known as c-fos-induced growth factor, or FIGF) is the most recently discovered member of the mammalian VEGF family17,32. The mature form of VEGFD shares 61% amino-acid sequence identity with VEGFC, and these two growth factors bind to the same receptors on human endothelial cells namely, VEGFR2 and VEGFR3 (REF. 17; FIG. 1). VEGFD is proteolytically processed in a similar way to VEGFC, and the proteolytic processing seems to regulate VEGFD biological activity and receptor specificity33. Interestingly, in mice, Vegfd binds only to Vegfr3, indicating that Vegfd might have a somewhat different function in mice and humans34. This is uncommon in the VEGF family as these homologous and evolutionarily conserved growth factors are assumed to have similar receptor-binding characteristics in different species. Mouse Vegfd is able to stimulate the proliferation of vascular endothelial cells and is angiogenic in vitro and in vivo 35. Like VEGFC, human VEGFD is lymphangiogenic when overexpressed in skin keratinocytes20. Little is known about the expression of VEGFD in physiological conditions, but its mrna has been observed in melanoma cells and fibroblasts, lung mesenchyme and in the adult vascular wall36. The exact roles of VEGFC and VEGFD during embryonic vascular development are likely to be different. In adults, VEGFC and VEGFD might regulate the response of lymphatic vessels in inflammatory processes and in the regeneration of tissues after trauma, but they might also have important roles in physiological and pathological angiogenesis in various conditions. The lymphangiogenic receptor VEGFR3 contains an extracellular domain that consists of seven immunoglobulin homology domains37,38, the fifth of which is proteolytically cleaved, and the resulting polypeptides remain linked by two disulphide bonds39 (FIG. 1). The cytoplasmic domain contains tyrosine kinase domains that are interrupted by a kinase insert sequence. In a recent study, lymphatic endothelial cells were isolated using monoclonal antibodies to VEGFR3 and grown in culture40. Stimulation of VEGFR3 alone protected these cells from serum-deprivation-induced apoptosis and induced cell growth and migration. At least some of these signals were transduced via a protein-kinase-c-dependent activation of the p42/p44 mitogen-activated protein kinase (MAPK) signalling cascade and via AKT phosphorylation40. The culture of lymphatic endothelial cells will allow further analysis of events that are associated with activation of the VEGFR3 lymphangiogenic signalling pathway. Markers of the lymphatic endothelium Although the lymphatic vessels were discovered approximately 300 years ago41 at the same time as the blood circulation was described42 the study of the lymphatic system has remained relatively neglected until recently. This has been, in part, due to the difficulties in recognizing lymphatics in tissues because of morphological criteria, such as their thin walls, compressed lumens (although lymphatics can be distinguished from blood vessels by a lack of pericytes) and a need for specific markers. Therefore, the recent discovery of a range of markers that show specificity for lymphatic endothelium has been a significant advance in the field of lymphangiogenesis (TABLE 1). VEGFR3 was originally thought to be expressed specifically in the lymphatic endothelium, but further studies revealed that it is also expressed in a small subset of blood vessels in normal tissues and, in addition, can be re-expressed in angiogenic blood vessels in certain pathological conditions43,44. Podoplanin is a glomerular podocyte membrane mucoprotein, which occurs together with VEGFR3 in the lymphatic endothelium and in benign vascular tumours and angiosarcomas, but it is also expressed in certain nonendothelial cells, such as osteoblastic cells, kidney podocytes and lung alveolar type I cells45,46. Podoplanin NATURE REVIEWS C ANCER VOLUME 2 AUGUST

4 Table 1 Markers exhibiting specificity for lymphatic endothelium within the vasculature Marker Function Sites of expression other than lymphatics References Desmoplakin Associates with desmosomal Epithelial cells and cardiac muscle 53,95 cadherins to form a cell-adhesion complex D6 β-chemokine receptor Expressed in a subset of lymphatics only 50 Secondary lymphoid Mediates lymphocyte Expressed in T-cell zones within lymph nodes 51,96 chemokine adhesion and migration through and lymphoid tissues, and constitutively tissues by acting as a expressed on the lymphatic endothelium of chemoattractant many tissues 5 -Nucleotidase Enzyme involved in nucleotide Weakly expressed on some blood vessels 54 metabolism LYVE1 Hyaluronan receptor on Blood sinusoidal endothelial cells in both liver 48,49, lymphatic endothelium and spleen, and placental syncytiotrophoblasts 97,98 Podoplanin 38-kDa membrane glycoprotein Osteoblastic cells, kidney podocytes and lung 45,46, of podocytes alveolar type 1 cells 99,100 PROX1 Homeobox protein involved in Non-endothelial cells in lens, heart, liver, 47,101 the formation of the lymphatics pancreas and nervous system VEGFR3 Growth-factor receptor, ligands Tumour blood vessels, highly fenestrated 25,43,44, are VEGFC and VEGFD; blood vessels and macrophages 72,102,103 signals for lymphangiogenesis is present in small lymphatics but not in larger ones that have smooth-muscle cells, whereas all blood vessels and high endothelial venules in the lymph nodes are negative for this protein. PROX1 is a homeobox transcription factor that is involved in the growth and elongation of lymphatic vessel sprouts during development 47, and its expression persists in adult lymphatic endothelium. It is also expressed in non-endothelial cells in the lens, heart, liver, pancreas and nervous system. Prox1 +/ mouse embryos develop chylous ascites and die within 2 3 days after birth, whereas Prox1 / mice have a completely absent lymphatic system 47. Another marker that is located on lymphatic endothelial cells, LYVE1 (lymphatic vessel endothelial hyaluronan receptor-1), is related to the CD44 receptor for hyaluronan. LYVE1 is distributed equally among the luminal and abluminal surfaces of lymphatic vessels and is involved in the uptake of hyaluronan by lymphatic endothelial cells and its transport from the tissues to the lymph 48. However, LYVE1 is not completely specific for lymphatic endothelial cells, as it is also present, for example, in normal hepatic blood sinusoidal endothelial cells 49. Recently, a β-chemokine receptor D6 was shown to be present in a subset of lymphatic vessels in the skin, intestine and lymphoid tissues 50. Interestingly, lymphatic vessels in most other organs remained negative for D6 immunoreactivity. The existence of this receptor on only a subset of lymphatics indicates a functional heterogeneity within the lymphatic vasculature. In addition, the secondary lymphoid chemokine SLC/6Ckine/exodus-2/CCL21 is a useful marker for lymphatic endothelium 51. Recent findings revealed coexpression of neuropilin-2 (an isoform-specific receptor for VEGF, VEGFB and placenta growth factor) and VEGFR3 in the lymphatic vessels 52. Desmoplakin and 5 -nucleotidase have also been used to distinguish the lymphatic from the blood-vascular endothelium 53,54, and as lymphatic capillaries lack a continuous basement membrane, immunohistochemistry for extracellular-matrix components such as type IV collagen and laminin have also been used to distinguish them from blood capillaries 55. VEGFR2 is occasionally expressed in lymphatic endothelium 56, and the cell-surface-receptor tyrosine kinases TIE1 and TIE2 might also have a role in lymphatic-vessel regulation, as they also appear in lymphatic endothelium 56,57 and in mice that are deficient for angiopoietin-2 (Ang2), a Tie2 ligand, that produces a lymphatic phenotype 120. In cultured lymphatic endothelial cells and in normal tissues, VEGFR3, LYVE1 and podoplanin were essentially located in the same cells 43,49,58. More information needs to be obtained to clarify the specificity of these markers in lymphatic vessels in disease processes. Until then, several markers should be used to confirm the staining of lymphatic vessels in pathological conditions. Lymphatic vessels in cancer A common clinical finding for many solid tumours, including carcinomas, is the spread of tumour cells through the lymphatics to regional lymph nodes 59,60. The detection of this event in the metastatic process is significant for both tumour staging and for designing treatment protocols 1, In particular, the analysis of sentinel lymph nodes has been developed as a method for the diagnosis and staging of a range of cancers, including melanoma and breast cancer The question of whether lymphatic vessels actually exist in solid tumours is still debated in the scientific and medical literature 12, The lack of markers to distinguish blood vessels from lymphatic vessels, and the difficulty in identifying these vessels by injection techniques, has meant that, in recent history, the evidence that linked lymphatics in solid tumours with the spread of cancer was not compelling AUGUST 2002 VOLUME 2

5 REVIEWS a Tumour angiogenesis increased tumour growth Vascular endothelial cells Macrophage Tumour-cell proliferation Chemotaxis VEGFR2 Stromal cell Tumour cell Unprocessed VEGF-C/D b Tumour lymphangiogenesis increased lymphatic metastasis Lymphatic endothelial cells Tumour-cell invasion Macrophage Chemotaxis VEGFR2 VEGFR3 Stromal cell Tumour cell Figure 3 Function of lymphangiogenic factors in tumour biology. The lymphangiogenic factors vascular endothelial growth factor-c (VEGFC) and VEGFD are produced by both tumour and stromal cells. a Processed VEGFC and VEGFD signal through the receptor VEGFR2, stimulating vascular endothelial cells and promoting angiogenesis. This supports the growth and proliferation of tumour cells. b Processed VEGFC and VEGFD can induce lymphangiogenesis by activating VEGFR3, which stimulates lymphatic endothelial cells. This promotes lymphatic metastasis in experimental tumour models18,19,21 and increases the ability of human cancer cells to metastasize to the lymphatics and local lymph nodes (see TABLE 2). VEGFC and VEGFD also have a role in immune modulation. VEGFC has been shown to be chemotactic for macrophages, which express VEGFR3. Macrophages also express and secrete lymphangiogenic factors, such as VEGFC and VEGFD72,121. Nevertheless, it has become clear that peritumoral lymphatics, which are often enlarged, are associated with human tumours68, whereas the existence of intratumoral lymphatics has been in doubt 69. It was long thought that lymphatics might be collapsed or could not penetrate into expanding primary tumours because of the high physical pressure inside tumours70. However, recently, intratumoral lymphatics and lymphangiogenesis have been observed19,21,68, and an interesting question is whether or not lymphatic-vessel density, in comparison to blood-vascular density, is related to prognosis and metastatic spread. Role of lymphangiogenesis in cancer spread Recent work using experimental animal models has highlighted the role of VEGFC and VEGFD in tumour biology (FIG. 3). Transgenic mice that overexpress VEGFC in β-cells of the pancreas (Rip-VEGFC, rat insulin promoter) developed extensive lymphangiogenesis around the endocrine islets of Langerhans18. Furthermore, when tumours were induced in these VEGFC-overexpressing islets by mating the mice with transgenic mice that express the SV40 T-antigen oncogene in the β-cells (Rip1-Tag2) metastatic tumour-cell aggregates of β-cell origin were observed in the surrounding lymphatic vessels. These mice also frequently developed metastases in the lymph nodes that drain the pancreas, whereas tumours in mice lacking the VEGFC transgene did not metastasize, nor were tumour cells observed inside the lymphatic vessels18. VEGFC overexpression did not significantly alter tumour volume, transition from adenoma to carcinoma or tumour angiogenesis but, interestingly, the tumour incidence was increased, the reasons for which are unknown. Similarly, human breast cancer cells expressing ectopic VEGFC were shown to induce lymphangiogenesis in and around the orthotopically implanted tumours19,71. Nevertheless, VEGFC did not have a significant effect on angiogenesis in these models, although it did promote tumour growth. VEGFC did, however, stimulate angiogenesis in another tumour model72. This apparent discrepancy might be related to the degree of proteolytic processing of VEGFC in each individual tumour model. In a breast cancer model, VEGFC promoted enhanced spreading of tumour cells to the regional lymph nodes, and the degree of tumour lymphangiogenesis correlated with lymph-node metastases73. VEGFC-induced tumour lymphangiogenesis, intralymphatic tumour growth and lymphatic metastasis could be inhibited by adenoviral expression of the soluble extracellular domain of VEGFR371,74. VEGFC expression by a tumour, however, is not always sufficient to induce the formation of functional NATURE REVIEWS C ANCER VOLUME 2 AUGUST

6 Table 2 Expression of VEGFC/VEGFD genes in the primary tumours Tumour Findings in relation to metastasis References VEGFC Breast cancer VEGFC protein expression correlated with lymphatic vessel invasion; disease- 104 free survival (5 years) of the VEGFC-positive group was significantly poorer* Cervical cancer Multivariate analysis revealed VEGFC mrna expression to be the sole 105 independent factor influencing pelvic lymph-node metastasis; patients with VEGFC mrna expression had significantly poorer prognosis* Colorectal cancer VEGFC mrna correlated with lymph-node metastasis, lymphatic involvement 106 and invasion depth* Tumours with lymph-node metastasis had higher levels of VEGF expression, 107 but there was no association between VEGFC expression and lymphatic spread* Endometrial carcinoma VEGFC protein expression correlated with vascular invasion, depth of invasion, 108 lymphatic-vessel invasion and lymph-node metastasis Oesophageal cancer VEGFC expression correlated with depth of invasion, tumour stage, venous 109 invasion, lymphatic invasion and lymph-node metastasis Gastric cancer Correlation between grade of VEGFC expression pattern and lymph-node status* 110 VEGFC expression correlated with lymphatic and venous invasion; 111 VEGFC expression had a significant negative impact on the prognosis of patients who did not express VEGF VEGFC protein expression was significantly 112 higher in lymphatic-invasion-positive early gastric cancer (EGC) than that in lymphatic-invasion-negative EGC; also, there was a tendancy for VEGFC to be expressed in node-positive/venous-invasion-positive EGC, compared with node-negative/venous-invasion-negative EGC Head and neck Increased expression of VEGF and VEGFC in tumours*; VEGFC expression had 86 squamous-cell carcinoma predictive value for the presence of cervical nodal metastases Lung adenocarcinoma Lymph-node metastasis associated with high levels of VEGFC expression; 85 a low VEGFD:VEGFC ratio correlated with lymphatic invasion* Neuroblastoma No correlation between VEGFC expression and lymph-node metastasis* 113 Non-small-cell lung cancer VEGF and VEGFC expression was associated with nodal microdissemination* 114 VEGFC expression was significantly associated with lymph-node metastasis, 115 lymphatic-vessel invasion and poor outcome Pancreatic cancer VEGFC expression was associated with increased lymphatic vessel invasion 116 and lymph-node metastasis, but not with decreased patient survival Prostate cancer VEGFC mrna was more abundant in lymph-node-positive patients 117 Thyroid tumours VEGFC expression correlates with lymph-node-invasive tumours* 118 VEGFD Colorectal cancer Tumours with lymph-node metastasis expressed higher levels of VEGF, but there 107 was no association of VEGFD expression with lymphatic spread* The expression of VEGFD correlated with lymphatic involvement and was found 87 to be an independent prognostic marker for disease-free and overall survival in colorectal carcinoma Lung adenocarcinoma Lymph-node metastasis associated with low VEGFD expression* 85 Head and neck Decreased expression of VEGFD associated with cervical-node metastases* 86 squamous-cell carcinoma *mrna expression detected by reverse transcription polymerase chain reaction; protein detected by immunohistochemistry; mrna expression detected by in situ hybridization; VEGF, vascular endothelial growth factor. lymphatic vessels 66. There might be variation between different tumour types, and the physical pressure exerted by the growing tumour might prevent the growth of lymphatic sprouts into the tumour an issue that has been debated extensively 69. VEGFD was also shown to promote the metastatic spread of tumour cells via the lymphatics in a mouse tumour model 21 (FIG. 3). In addition to lymphangiogenesis and increased metastasis, the tumours that secrete VEGFD also showed an increase of both growth rate and angiogenesis. The growth of the tumour, angiogenesis and formation of metastases were all inhibited by a neutralizing antibody to the bioactive region of VEGFD. The differences between the tumour-angiogenic properties of VEGFC and VEGFD might have been due to differences in their proteolytic processing in the different models. Some of the heterogeneity in the effects of these growth factors could also result from variable expression of their receptors Vegfr2 and Vegfr3 on the blood-vascular and lymphatic endothelia. In the above case, in particular, enhanced tumour angiogenesis was probably observed for VEGFD because of its increased proteolytic processing, which resulted in an increased affinity to Vegfr2 (REF. 21), when compared with the VEGFC models. Consistent with this theory, the vascular effects of VEGFC in experimental tumours were reduced when the 578 AUGUST 2002 VOLUME 2

7 mice were treated with blocking antibodies against Vegfr2 (REF. 75). Intratumoral lymphatic vessels were observed in xenograft models 19,21,71, but not in a transgenic mouse tumour model 18. This could be partially explained by the trapping of vessels in between the rapidly growing tumour foci in the xenografts. On the basis of these observations, tumour-vessel formation can be dissected into pathways that preferentially activate angiogenesis (driven by VEGFR2) and pathways that preferentially activate lymphangiogenesis (driven by VEGFR3), although there is evidence that the receptors share overlapping expression patterns 56. Activation of lymphatic endothelial cells by tumour-cell-secreted factors might promote the interaction of tumour cells with lymphatic endothelial cells, and thereby facilitate tumour-cell entry into the lymphatics. In spite of the increased metastatic tendency of VEGFC-overexpressing tumour cells, metastases were seen only in a subset of the tumourbearing mice. Overall, on the basis of studies in which VEGFC or VEGFD have been overexpressed in tumours, it could be that there are additional, rate-limiting steps in the metastatic process 74.The simplest explanation for the metastasis-enhancing effects of VEGFC and VEGFD is that they eliminate one rate-limiting step by increasing the contact surface area between invading tumour cells and hyperplastic lymphatic endothelium. They could also, however, facilitate metastasis by increasing vascular permeability or by changing the adhesive properties or cytokine or chemokine expression patterns of the lymphatic endothelium. VEGFC and VEGFD that are secreted by tumour cells could also have important effects on the tumour interstitial-fluid pressure. VEGFC can increase vascular leakage but not as efficiently as VEGF although a parallel increase in lymphangiogenesis could alleviate this effect. The increased interstitial fluid pressure could be a significant determinant of tumour-cell seeding into the blood vascular and lymphatic circulation: recent studies have shown that a proportion of the lumens of tumour blood vessels contain tumour cells 76,77. It is not known to what extent tumour-cell-secreted factors are directly responsible for the large lymphatic vessels that are occasionally detected around human tumours. Inflammatory cells, for example, could contribute to the lymphangiogenesis, as VEGFC is chemotactic for macrophages 72 and readily induced by proinflammatory cytokines 26,27. It is not clear whether the newly formed lymphatic vessels mature in a similar way to the blood vessels, or whether they are more prone to tumour-cell invasion, for example, because of differences in the expression of adhesion receptors. VEGF is known to be able to upregulate the expression of adhesion molecules in the vasculature 78,but such a role for VEGFC and VEGFD is not known. Although it seems evident that both VEGFC and VEGFD can induce the growth of new lymphatic vessels, several questions remain unanswered regarding tumour lymphangiogenesis and metastasis. For example, it is not known whether it is sufficient for pre-existing lymphatic vessels to expand by circumferential growth, or whether new vessels are required for the enhancement of the metastatic process. The intratumoral lymphatic vessels observed are usually collapsed, presumably due to the high physical pressure in solid tumours, which might impair their transport capacity. Also, as in angiogenesis, lymphangiogenesis might occur by several mechanisms, and different regulatory factors might be involved. One example of such a factor is fibroblast growth factor-2 (FGF2), which can promote both angiogenesis and lymphangiogenesis 79. VEGFR3 might also be involved in tumour angiogenesis, in addition to its function in tumour lymphangiogenesis. It has been reported to be expressed in blood-vessel capillaries during tumour angiogenesis 44,80. Inactivation of Vegfr3 by neutralizing antibodies suppressed tumour growth by destabilizing large blood vessels in xenograft mouse models. Microhaemorrhages were seen in these vessels, indicating that Vegfr3 could be involved in maintaining the integrity of the endothelial-cell lining in the neovasculature 81. Frequent Vegfr3 antibody administration was required for the suppression of tumour growth, but the architecture of the non-angiogenic blood and lymphatic vessels remained unaffected. It has also been shown that even a prolonged suppression of Vegf activity in adult mice has no effect on the maintenance of the vascular system, although it suppressed angiogenesis severely in embryos 82. The fully established blood and lymphatic vessels seem to be resistant to treatment with these kinds of anti-angiogenic agents. It is still unknown whether VEGFC or VEGFD promotes lymphangiogenesis in human tumours, and, if so, whether or not this increases the rate of metastasis to the lymph nodes. VEGFC expression has been detected in about half of the human cancers analysed 83.Several reports have described a correlation between VEGFC expression in human tumours and the formation of metastases in regional lymph nodes. So far, VEGFC levels in primary tumours have been shown to correlate significantly with lymph-node metastases in thyroid, prostate, gastric, colorectal, lung and oesophageal carcinomas (see TABLE 2). Less is known about the presence of VEGFD in human tumours, but this growth factor was shown to be upregulated in human melanomas when compared with melanocytes 36. VEGFD was detected in melanoma cells, as well as in vessels that are adjacent to VEGFD-expressing tumour cells, but not in vessels that are distant from the tumours. This indicates that VEGFD binds to the endothelial cells of nearby vessels and contributes in a paracrine manner to the regulation of tumour angiogenesis and lymphangiogenesis a model that is supported by recent analysis of VEGFD protein and mrna in non-small-cell lung cancer 84. VEGFD expression, by contrast, was inversely correlated with lymph-node metastasis in lung adenocarcinoma 85 and head and neck squamous-cell carcinoma 86. Interestingly, expression of VEGFD was recently identified as an independent prognostic marker for both disease-free and overall survival in colorectal carcinoma and correlated with lymphatic involvement for this NATURE REVIEWS CANCER VOLUME 2 AUGUST

8 Table 3 Potential inhibitors of the lymphangiogenic signalling pathway Potential inhibitor Mode of action Site of action References Soluble extracellular domain of VEGFR3 Sequester VEGFC and VEGFD Extracellular 71,89 Soluble extracellular domain of VEGFR2 Sequester VEGFC and VEGFD; also Extracellular 119 sequester VEGFA Neutralizing monoclonal antibodies to Block interactions with VEGFR3 and VEGFR2 Extracellular 21,88 VEGFC and VEGFD Neutralizing monoclonal antibodies to Block interactions with VEGFC and VEGFD Cell surface 81 VEGFR3 Peptidomimetics based on VEGFC Block binding of VEGFC/D with VEGFR3 Cell surface and/or VEGFD Inhibitors of tyrosine kinase activity Block signalling by VEGFR3 Cytoplasm 91,92 of VEGFR3 Inhibitors of molecules that signal Block signalling downstream of VEGFR3 Cytoplasm 40 downstream of activated VEGFR3 VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth-factor receptor. LYMPHOEDEMA A condition in which fluid drainage from tissue is insufficient due to a dysfunctional or overloaded lymphatic system. tumour type 87. The reason that VEGFD expression correlates with metastasis in some tumours, but has an inverse correlation with metastasis in others, could be due, in part, to different degrees of proteolytic processing of this growth factor in different tumours, or expression of other lymphangiogenic factors. In a recent study, proliferating intra-tumoral lymphatics were observed in discrete hotspots in a subset of human head and neck squamous-cell carcinomas and correlated with lymphnode metastasis at least in the case of oropharyngeal carcinoma 68. These intratumoral lymphatics were immature in morphology with small lumens and comprise only a small number of endothelial cells. Although, in this study, the presence of these proliferating intratumoral lymphatics did not seem to correlate with VEGFC expression, further analysis will be required to thoroughly assess the role of VEGFC and VEGFD in the regulation of these vessels. Inhibition of lymphangiogenesis Despite advances in surgery, radiotherapy and chemotherapy, the prognosis of many cancers remains poor, so new approaches for anti-metastatic therapy would be most welcome. Inhibitors that block the VEGFC/VEGFD/VEGFR3 signalling pathway that controls tumour lymphangiogenesis might have the potential to block lymphogenous metastatic spread. Monoclonal antibodies (mabs) that antagonize the interaction of VEGFC and VEGFD with the ligand-binding domain of VEGFR3 would be useful inhibitors of this pathway (TABLE 3). It was recently reported that a neutralizing VEGFD mab (VD1) that blocks interactions with Vegfr2 and Vegfr3 (REF. 88) inhibited angiogenesis, lymphangiogenesis and metastatic spread via the lymphatics in a mouse tumour model 21. A mab against Vegfr3 that blocked the binding of Vegfc induced micro-haemorrhage from tumour blood vessels in a mouse cancer model although the effects on tumour lymphatics were not analysed 81. One alternative to antibodies would be to use a soluble version of the extracellular domain of VEGFR3 to sequester VEGFC and VEGFD. A study in which a transgenic mouse expressed the extracellular domain of VEGFR3 in skin keratinocytes under the control of the keratin 14 gene promoter showed that depletion of the ligands for VEGFR3 with this domain inhibited the formation of lymphatic vessels in the embryo 89. Additionally, adenoviral-mediated delivery of the soluble receptor domain blocked the growth of peritumoral lymphatic vessels in a mouse model of breast cancer 71 and inhibited lymph-node metastasis, but not lung metastasis, in a lung cancer model 74. Another approach for inhibiting the lymphangiogenic signalling pathway would be to use orally active small molecules that interfere with the binding of VEGFC/VEGFD to VEGFR3, or that inhibit the tyrosine kinase catalytic domain of this receptor. The potential of such approaches has been illustrated by recent studies showing that inhibitors of the tyrosine kinase catalytic domain of the closely related VEGFR2 block tumour angiogenesis at least in animal models 90,91. Interestingly, a set of indolinones have been described that inhibit the catalytic activity of VEGFR3, but not VEGFR2 (REF. 92). The effects of these compounds in vivo, however, have not yet been reported. One potential complication of targeting the VEGFR3 signalling pathway is that lymphatic-vessel function in normal tissues could be effected. Little is known about the role of VEGFR3 in the maintenance and function of mature lymphatics. It will therefore be crucial to carefully monitor the effects of anti-lymphangiogenic approaches especially those that target the VEGFR3 signalling pathway on the integrity and function of mature lymphatics in normal adult tissues. Clinical use of pro-lymphangiogenesis An important function of the lymphatics is to regulate the pressure of interstitial fluid in tissues by transporting excess fluid back into the circulation. Oedema represents an imbalance between lymph formation and its absorption into the lymphatic vessels. Clinical situations in which the lymphatic system is involved include LYMPHOEDEMA due to impaired lymphatic drainage. Lymphoedema can be hereditary (primary lymphoedema; Milroy s disease) or caused by inflammatory or neoplastic obstruction of the lymphatic vessels, including accumulation of ascites 580 AUGUST 2002 VOLUME 2

9 fluid due to peritoneal carcinomatosis or oedema of the arm following surgery or radiotherapy for breast cancer (secondary lymphoedema). Lymphoedema is treated, at present, by manual lymphatic drainage and by compressive garments. The discovery of specific genes that are involved in the regulation of lymphatic vessels, and in the pathology of lymphoedema, should make the design of targeted treatments for this condition possible. Several mouse models have recently shown that VEGFC and VEGFD can be used to stimulate lymphangiogenesis and are, therefore, potential treatments for lymphoedema 16,20,52,93.Such therapy could be used in non-hereditary, regional forms of lymphoedema that result from surgery or lymphaticvessel destruction after cancer therapy. As VEGFR3 signalling has a role in lymphatic endothelial-cell survival 58,94, long-term growth-factor expression might be needed to induce lymphangiogenesis and maintain these vessels in patients with chronic lymphoedema. The functional characteristics of the newly formed lymphatic vessels such as their connections to draining lymphatic vessels still require additional studies. Future directions Blood and lymphatic vessels are formed in an interactive manner during embryonic development, but both vessel types are maintained in a rather quiescent state in adults and are active only in sites of new tissue growth. Angiogenesis has been extensively studied for over a decade, but lymphangiogenesis is a relatively new topic for vascular biology. As lymphatic vessels are important for the spread of cancer, lymph-node metastasis is an effective prognostic indicator, and partly determines the therapeutic approaches for cancer treatment. The discovery of molecules that are involved in the biology of lymphatic vessels, lymphatic-specific markers and techniques for culturing lymphatic endothelial cells has enabled a more extensive study of the many roles of the lymphatics in developing tissues and cancer. VEGFC and VEGFD both stimulate the growth of lymphatic vessels, being the first growth factors found for lymphatic endothelial cells. Encouraging results have recently been observed from animal models in which blocking the VEGFC/VEGFD/VEGFR3 signalling pathways led to inhibition of metastatic spread of tumour cells via the lymphatic vasculature. Conversely, stimulation of this signalling pathway shows promise for the treatment of lymphoedema. Clinical trials using these strategies will reveal the potential of anti-lymphangiogenics in treating human cancer. 1. Wen, P. Y., Black, P. M. & Loeffler, J. S. in Cancer. Principles and Practice of Oncology (eds De Vita, V. J., Helman, S. & Rosenberg, S. A.) (Lippincott Williams & Wilkins, Philadelphia, 2001). 2. Fidler, I. J. in Cancer: Principles & Practice of Oncology (eds De Vita, V. J., Helman, S. & Rosenberg, S. A.) (Lippincott Raven Publishers, Philadelphia, 1997). 3. Stetler-Stevenson, W. G. & Kleiner Jr., D. E. in Cancer: Principles and Practice of Oncology (eds De Vita, V. J., Helman, S. & Rosenberg, S. A.) (Lippincott Williams & Wilkins, Philadelphia, 2001). 4. Butler, T. P. & Gullino, P. M. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 35, (1975). 5. Ruoslahti, E. How cancer spreads. Sci. Am. 275, (1996). 6. Folkman, J. & Klagsburn, M. Angiogenic factors. Science 235, (1987). 7. Folkman, J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, (1995). 8. Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, (1993). 9. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W. & Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant negative Flk-1 mutant. Nature 367, (1994). 10. Saleh, M., Stacker, S. A. & Wilks, A. F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56, (1996). 11. Weidner, N., Semple, J. P., Welch, W. R. & Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1 8 (1991). 12. Clarijs, R., Ruiter, D. J. & de Waal, R. M. Lymphangiogenesis in malignant tumours: does it occur? J. Pathol. 193, (2001). 13. Karpanen, T. & Alitalo, K. Lymphatic vessels as targets of tumor therapy. J. Exp. Med. 194, F37 F42 (2001). 14. Sleeman, J. P., Krishnan, J., Kirkin, V. & Baumann, P. Markers for the lymphatic endothelium: in search of the holy grail? Microsc. Res. Tech. 55, (2001). 15. Oh, S.-J. et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev. Biol. 188, (1997). 16. Jeltsch, M. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276, (1997). Demonstration in vivo that overexpression of VEGFC induces the growth of pre-existing lymphatic vessels in the skin of transgenic mice. 17. Achen, M. G. et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk-1) and VEGF receptor 3 (Flt-4). Proc. Natl Acad. Sci. USA 95, (1998). Shows that VEGFD (previously described as a growth factor for fibroblasts see reference 32) is a ligand for VEGFR2 and VEGFR3, thereby defining the subfamily of lymphangiogenic growth factors (which consists of VEGFD and VEGFC). 18. Mandriota, S. J. et al. Vascular endothelial growth factor-cmediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20, (2001). Reports that expression of VEGFC in the Rip-Tag mouse model confers on islet-cell tumours the ability to spread to regional lymph nodes. 19. Skobe, M. et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Med. 7, (2001). Shows that overexpression of VEGFC in a human tumour xenograft is capable of inducing lymphangiogenesis, which mediates lymphatic metastasis. 20. Veikkola, T. et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20, (2001). 21. Stacker, S. A. et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nature Med. 7, (2001). Shows the capacity of VEGFD to speed tumour growth by promoting angiogenesis. VEGFD also stimulated tumour lymphangiogenesis and lymphatic metastasis, which could be specifically inhibited with an anti-vegfd monoclonal antibody. In this model, overexpression of VEGF caused an increase in tumour angiogenesis and growth, but did not stimulate lymphangiogenesis or the spread of cancer cells to the lymphatics. 22. Joukov, V. et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15, (1996). 23. Lee, J. et al. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl Acad. Sci. USA 93, (1996). 24. Joukov, V. et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16, (1997). Demonstration that the lymphangiogenic factor VEGFC is processed by proteolysis to generate a form that binds receptors with high affinity and activates VEGFR2 and VEGFR Kaipainen, A. et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl Acad. Sci. USA 92, (1995). 26. Enholm, B. et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mrna regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14, (1997). 27. Ristimaki, A., Narko, K., Enholm, B., Joukov, V. & Alitalo, K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-c. J. Biol. Chem. 273, (1998). 28. Kukk, E. et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122, (1996). 29. Cao, Y. et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl Acad. Sci. USA 95, (1998). 30. Witzenbichler, B. et al. Vascular endothelial growth factor-c (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 153, (1998). 31. Pepper, M. S., Mandriota, S. J., Jeltsch, M., Kumar, V. & Alitalo, K. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J. Cell. Physiol. 177, (1998). 32. Orlandini, M., Marconcini, L., Ferruzzi, R. & Oliviero, S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl Acad. Sci. USA 93, (1996). 33. Stacker, S. A. et al. Biosynthesis of vascular endothelial growth factor-d involves proteolytic processing which generates non-covalent homodimers. J. Biol. Chem. 274, (1999). 34. Baldwin, M. E. et al. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. J. Biol. Chem. 276, (2001). NATURE REVIEWS CANCER VOLUME 2 AUGUST

Signaling Vascular Morphogenesis and Maintenance

Signaling Vascular Morphogenesis and Maintenance Signaling Vascular Morphogenesis and Maintenance Douglas Hanahan Science 277: 48-50, in Perspectives (1997) Blood vessels are constructed by two processes: vasculogenesis, whereby a primitive vascular

More information

The Angiopoietin Axis in Cancer

The Angiopoietin Axis in Cancer Ang2 Ang1 The Angiopoietin Axis in Cancer Tie2 An Overview: The Angiopoietin Axis Plays an Essential Role in the Regulation of Tumor Angiogenesis Growth of a tumor beyond a limiting size is dependent upon

More information

Neoplasia 18 lecture 8. Dr Heyam Awad MD, FRCPath

Neoplasia 18 lecture 8. Dr Heyam Awad MD, FRCPath Neoplasia 18 lecture 8 Dr Heyam Awad MD, FRCPath ILOS 1. understand the angiogenic switch in tumors and factors that stimulate and inhibit angiogenesis. 2. list the steps important for tumor metastasis

More information

VEGFR-3 in Angiogenesis and Lymphangiogenesis

VEGFR-3 in Angiogenesis and Lymphangiogenesis VEGFR-3 in Angiogenesis and Lymphangiogenesis Lotta Jussila Molecular/Cancer Biology Laboratory Haartman Institute and Helsinki University Central Hospital Biomedicum Helsinki University of Helsinki Finland

More information

1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications

1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications Metastasis 1.The metastatic cascade 2.Pathologic features of metastasis 3.Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of bone Paget s disease of the

More information

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize? 1. The metastatic cascade 3. Pathologic features of metastasis 4. Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of Paget s disease of the nipple (intraductal

More information

Angiogenesis as a therapeutic target

Angiogenesis as a therapeutic target Angiogenesis as a therapeutic target Lecture Experimentelle Krebsforschung SS 07 Prof. Gerhard Christofori Institute of Biochemistry and Genetics Department of Clinical-Biological Sciences University of

More information

Cancer Biology Course. Invasion and Metastasis

Cancer Biology Course. Invasion and Metastasis Cancer Biology Course Invasion and Metastasis 2016 Lu-Hai Wang NHRI Cancer metastasis Major problem: main reason for killing cancer patients, without it cancer can be cured or controlled. Challenging questions:

More information

Lymphangiogenesis and lymphatic metastasis in breast cancer

Lymphangiogenesis and lymphatic metastasis in breast cancer Pathophysiology 17 (2010) 229 251 Review Lymphangiogenesis and lymphatic metastasis in breast cancer Sophia Ran, Lisa Volk, Kelly Hall, Michael J. Flister Department of Medical Microbiology, Immunology

More information

PBS Class #2 Introduction to the Immune System part II Suggested reading: Abbas, pgs , 27-30

PBS Class #2 Introduction to the Immune System part II Suggested reading: Abbas, pgs , 27-30 PBS 803 - Class #2 Introduction to the Immune System part II Suggested reading: Abbas, pgs. 15-25, 27-30 Learning Objectives Compare and contrast the maturation of B and T lymphocytes Compare and contrast

More information

Tissue renewal and Repair. Nisamanee Charoenchon, PhD Department of Pathobiology, Faculty of Science

Tissue renewal and Repair. Nisamanee Charoenchon, PhD   Department of Pathobiology, Faculty of Science Tissue renewal and Repair Nisamanee Charoenchon, PhD Email: nisamanee.cha@mahidol.ac.th Department of Pathobiology, Faculty of Science Topic Objectives 1. Describe processes of tissue repair, regeneration

More information

Computational Systems Biology: Biology X

Computational Systems Biology: Biology X Bud Mishra Room 1002, 715 Broadway, Courant Institute, NYU, New York, USA L#5:(October-18-2010) Cancer and Signals Outline 1 2 Outline 1 2 Cancer is a disease of malfunctioning cells. Cell Lineage: Adult

More information

Neoplasia literally means "new growth.

Neoplasia literally means new growth. NEOPLASIA Neoplasia literally means "new growth. A neoplasm, defined as "an abnormal mass of tissue the growth of which exceeds and is uncoordinated with that of the normal tissues and persists in the

More information

Cytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,

Cytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins, Cytokines http://highered.mcgraw-hill.com/sites/0072507470/student_view0/chapter22/animation the_immune_response.html Cytokines modulate the functional activities of individual cells and tissues both under

More information

Inflammatory Cells and Metastasis

Inflammatory Cells and Metastasis Inflammatory Cells and Metastasis Experimentelle Krebsforschung SS 07 Gerhard Christofori Institute of Biochemistry and Genetics Department of Clinical-Biological Sciences Center of Biomedicine University

More information

TITLE: Notch in Pathological Angiogenesis and Lymphangiogenesis

TITLE: Notch in Pathological Angiogenesis and Lymphangiogenesis Award Number: W81XWH-10-1-0304 TITLE: Notch in Pathological Angiogenesis and Lymphangiogenesis PRINCIPAL INVESTIGATOR: Minji Kim CONTRACTING ORGANIZATION: Columbia University New York, NY 10032 REPORT

More information

SIBLINGs, cancer's multifunctional weapons

SIBLINGs, cancer's multifunctional weapons SIBLINGs, cancer's multifunctional weapons 6/18/08 Akeila Bellahcène and Vincent Castronovo of the Metastasis Research laboratory of the University of Liège are among the first researchers to have discovered

More information

Heterotypy and Angiogenesis

Heterotypy and Angiogenesis Heterotypy and Angiogenesis Tumors are perpetual wounds 1. Normally stroma and epithelia converse at a distance. 2. Juxtaposition of stroma and epithelia is indicative of tissue damage. 4. Activate strategies

More information

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD

More information

number Done by Corrected by Doctor Maha Shomaf

number Done by Corrected by Doctor Maha Shomaf number 21 Done by Ahmad Rawajbeh Corrected by Omar Sami Doctor Maha Shomaf Ability to Invade and Metastasize The metastatic cascade can be subdivided into two phases: 1-invasion of ECM and vascular dissemination:

More information

Tissue repair. (3&4 of 4)

Tissue repair. (3&4 of 4) Tissue repair (3&4 of 4) What will we discuss today: Regeneration in tissue repair Scar formation Cutaneous wound healing Pathologic aspects of repair Regeneration in tissue repair Labile tissues rapid

More information

CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION

CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION What is Cytokine? Secreted popypeptide (protein) involved in cell-to-cell signaling. Acts in paracrine or autocrine fashion through specific cellular receptors.

More information

HEM- AND LYMPH- ANGIOGENESIS IN CANCER METASTASIS

HEM- AND LYMPH- ANGIOGENESIS IN CANCER METASTASIS From THE DEPARTMENT OF MICROBIOLOGY, TUMOR AND CELL BIOLOGY Karolinska Institutet, Stockholm, Sweden HEM- AND LYMPH- ANGIOGENESIS IN CANCER METASTASIS Hong Ji Stockholm 2013 All previously published papers

More information

Review of relationship between vascular endothelial growth factor family & receptors and tumor angiogenesis

Review of relationship between vascular endothelial growth factor family & receptors and tumor angiogenesis 16 1 2004 2 hinese Bulletin of Life Sciences Vol. 16, No. 1 Feb., 2004 1004-0374 (2004) 01-0019-05 1 201203 2 200025 (vascular endothelial growth factor, ) (vascular permeability factor, VPF), -A -B -

More information

Disorders of Cell Growth & Neoplasia. Lecture 4 Molecular basis of cancer

Disorders of Cell Growth & Neoplasia. Lecture 4 Molecular basis of cancer General Pathology VPM 152 Disorders of Cell Growth & Neoplasia Lecture 4 Molecular basis of cancer Enrique Aburto Apr 2010 Skin tumor in a 10-year-old Rottweiler. Considering the external appearance and

More information

Disorders of Cell Growth & Neoplasia

Disorders of Cell Growth & Neoplasia General Pathology VPM 152 Disorders of Cell Growth & Neoplasia Lecture 3 Rate of growth, local invasion, and metastasis. Molecular basis of cancer (normal cell-cycle and cellular proliferation). Enrique

More information

LYMPHANGIOGENESIS REVIEWS THE RELATIONSHIP BETWEEN TUMORS AND THE LYMPHATICS: WHAT MORE IS THERE TO KNOW?

LYMPHANGIOGENESIS REVIEWS THE RELATIONSHIP BETWEEN TUMORS AND THE LYMPHATICS: WHAT MORE IS THERE TO KNOW? 62 Lymphology 39 (2006) 62-68 LYMPHANGIOGENESIS REVIEWS THE RELATIONSHIP BETWEEN TUMORS AND THE LYMPHATICS: WHAT MORE IS THERE TO KNOW? J.P. Sleeman Forschungszentrum Karlsruhe, Institut für Toxikologie

More information

Vascular Endothelial Growth Factor Expression in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma

Vascular Endothelial Growth Factor Expression in Oral Epithelial Dysplasia and Oral Squamous Cell Carcinoma OMPJ Vascular Endothelial Growth Factor Expression in Oral Epithelial Dysplasia 10.5005/jp-journals-10037-1003 and Oral Squamous Cell Carcinoma ORIGINAL RESEARCH Vascular Endothelial Growth Factor Expression

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes: Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,

More information

Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer

Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,

More information

Lymphoid System: cells of the immune system. Answer Sheet

Lymphoid System: cells of the immune system. Answer Sheet Lymphoid System: cells of the immune system Answer Sheet Q1 Which areas of the lymph node have most CD3 staining? A1 Most CD3 staining is present in the paracortex (T cell areas). This is towards the outside

More information

number Done by Corrected by Doctor Maha Shomaf

number Done by Corrected by Doctor Maha Shomaf number 19 Done by Waseem Abo-Obeida Corrected by Abdullah Zreiqat Doctor Maha Shomaf Carcinogenesis: the molecular basis of cancer. Non-lethal genetic damage lies at the heart of carcinogenesis and leads

More information

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,

More information

CD34 + VEGFR-3 + progenitor cells have a potential to differentiate towards lymphatic endothelial cells

CD34 + VEGFR-3 + progenitor cells have a potential to differentiate towards lymphatic endothelial cells CD34 + VEGFR-3 + progenitor cells have a potential to differentiate towards lymphatic endothelial cells Tan YZ et al. J Cell Mol Med. (2014 Mar;18(3):422-33) Denise Traxler-Weidenauer April 2014 Introduction

More information

FGL2 A new biomarker for cancer in a simple blood test

FGL2 A new biomarker for cancer in a simple blood test FGL2 A new biomarker for cancer in a simple blood test WHO IS FGL2 Human gene (chromosome 7) is 7 kb long, 2 exons, monomer protein 70 KD, tetramer in solution. Fibrinogen-like protein 2 (Fgl2), a member

More information

PATHOBIOLOGY OF NEOPLASIA

PATHOBIOLOGY OF NEOPLASIA PATHOBIOLOGY OF NEOPLASIA Department of Pathology Gadjah Mada University School of Medicine dr. Harijadi Blok Biomedis, 6 Maret 2009 [12] 3/17/2009 1 The pathobiology of neoplasia Normal cells Malignant

More information

LYMPHANGIOGENESIS REVIEWS THE EMERGENCE OF MOLECULAR AND TRANSGENIC LYMPHOLOGY: WHAT DO WE (REALLY) KNOW SO FAR?

LYMPHANGIOGENESIS REVIEWS THE EMERGENCE OF MOLECULAR AND TRANSGENIC LYMPHOLOGY: WHAT DO WE (REALLY) KNOW SO FAR? 1 Lymphology 39 (2006) 1-7 LYMPHANGIOGENESIS REVIEWS THE EMERGENCE OF MOLECULAR AND TRANSGENIC LYMPHOLOGY: WHAT DO WE (REALLY) KNOW SO FAR? C. Suri Independent Biotechnology Consultant,* Tarrytown, New

More information

The Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis

The Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis The Process of Angiogenesis & Inhibition of Angiogenesis and/or Lymphangiogenesis Nam Deuk Kim, Ph.D. Pusan National University Contents Part 1. The process of angiogenesis Part 2. The role of angiopoietins

More information

The Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D.

The Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D. The Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D. OBJECTIVES 1. To understand how ordered Ig gene rearrangements lead to the development

More information

Invasion And Metastasis. Wirsma Arif Harahap Surgical Oncologist Surgery Department Andalas Medical Schoool

Invasion And Metastasis. Wirsma Arif Harahap Surgical Oncologist Surgery Department Andalas Medical Schoool Invasion And Metastasis Wirsma Arif Harahap Surgical Oncologist Surgery Department Andalas Medical Schoool Biology of tumor growth The natural history of malignant tumors can be divided into four phase:

More information

VEGF-C/VEGFR-3 AND PDGF-B/PDGFR-ß PATHWAYS IN EMBRYONIC LYMPHANGIOGENESIS

VEGF-C/VEGFR-3 AND PDGF-B/PDGFR-ß PATHWAYS IN EMBRYONIC LYMPHANGIOGENESIS Helsinki University Biomedical Dissertations No. 112 VEGF-C/VEGFR-3 AND PDGF-B/PDGFR-ß PATHWAYS IN EMBRYONIC LYMPHANGIOGENESIS Paula Haiko Molecular/Cancer Biology Laboratory Haartman Institute and Biomedicum

More information

S pecific monoclonal antibodies (MoAbs) recognising the

S pecific monoclonal antibodies (MoAbs) recognising the 202 ORIGINAL ARTICLE LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer M I Koukourakis, A Giatromanolaki, E Sivridis, C Simopoulos, K C Gatter, A L Harris, D G Jackson...

More information

Sinusoids and venous sinuses

Sinusoids and venous sinuses LYMPHOID SYSTEM General aspects Consists of organs that are made of lymphoid tissue; Immune defense Breakdown of red blood cells. 1 Sinusoids In place of capillaries Endothelium; often fenestrated More

More information

Processing of VEGF-C and -D by the Proprotein Convertases: Importance in Angiogenesis, Lymphangiogenesis, and Tumorigenesis

Processing of VEGF-C and -D by the Proprotein Convertases: Importance in Angiogenesis, Lymphangiogenesis, and Tumorigenesis Processing of VEGF-C and -D by the Proprotein Convertases: Importance in Angiogenesis, Lymphangiogenesis, and Tumorigenesis ii Colloquium Digital Library of Life Sciences This e-book is an original work

More information

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some

More information

Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis

Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis Original papers Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis Aydan Eroğlu 1, A F, Cevriye Ersöz 2,

More information

Neoplasia 2018 Lecture 2. Dr Heyam Awad MD, FRCPath

Neoplasia 2018 Lecture 2. Dr Heyam Awad MD, FRCPath Neoplasia 2018 Lecture 2 Dr Heyam Awad MD, FRCPath ILOS 1. List the differences between benign and malignant tumors. 2. Recognize the histological features of malignancy. 3. Define dysplasia and understand

More information

Chapter 6. Villous Growth

Chapter 6. Villous Growth Core Curriculum in Perinatal Pathology Chapter 6 Villous Growth Overview of vasculogenesis and angiogenesis Vasculogenesis Extraembryonic Vasculogenesis Angiogenesis Branching angiogenesis Sprouting angiogenesis

More information

LYMPH GLAND. By : Group 1

LYMPH GLAND. By : Group 1 LYMPH GLAND By : Group 1 ANATOMY LYMPH NODE Lymphatic Organs Red bone marrow Thymus gland Lymph nodes Lymph nodules Spleen Primary organs Secondary organs Lymph Nodes Firm, smooth-surfaced, bean-shaped

More information

VEGF-C INDUCED LYMPHANGIOGENESIS IS ASSOCIATED WITH LYMPH NODE METASTASIS IN ORTHOTOPIC MCF-7 TUMORS

VEGF-C INDUCED LYMPHANGIOGENESIS IS ASSOCIATED WITH LYMPH NODE METASTASIS IN ORTHOTOPIC MCF-7 TUMORS Int. J. Cancer: 98, 946 951 (2002) 2002 Wiley-Liss, Inc. DOI 10.1002/ijc.10283 SHORT REPORT Publication of the International Union Against Cancer VEGF-C INDUCED LYMPHANGIOGENESIS IS ASSOCIATED WITH LYMPH

More information

In vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG)

In vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG) In vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG) 1 Dr Saeb Aliwaini 13/11/2015 Migration in vivo Primary tumors are responsible for only about 10%

More information

CHAPTER VII CONCLUDING REMARKS AND FUTURE DIRECTION. Androgen deprivation therapy is the most used treatment of de novo or recurrent

CHAPTER VII CONCLUDING REMARKS AND FUTURE DIRECTION. Androgen deprivation therapy is the most used treatment of de novo or recurrent CHAPTER VII CONCLUDING REMARKS AND FUTURE DIRECTION Stathmin in Prostate Cancer Development and Progression Androgen deprivation therapy is the most used treatment of de novo or recurrent metastatic PCa.

More information

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval Biochemistry of Carcinogenesis Lecture # 35 Alexander N. Koval What is Cancer? The term "cancer" refers to a group of diseases in which cells grow and spread unrestrained throughout the body. It is difficult

More information

Award Number: W81XWH TITLE: PRINCIPAL INVESTIGATOR: Michael Dellinger

Award Number: W81XWH TITLE: PRINCIPAL INVESTIGATOR: Michael Dellinger AD Award Number: W81XWH-10-1-0052 TITLE: PRINCIPAL INVESTIGATOR: Michael Dellinger CONTRACTING ORGANIZATION: UT Southwestern Medical Center Dallas, TX 75390 REPORT DATE: February 2013 TYPE OF REPORT: Annual

More information

Molecular and Cellular Basis of Immune Protection of Mucosal Surfaces

Molecular and Cellular Basis of Immune Protection of Mucosal Surfaces Molecular and Cellular Basis of Immune Protection of Mucosal Surfaces Department of Biologic & Materials Sciences School of Dentistry University of Michigan Ann Arbor, Michigan 48109-1078 1 Image quality

More information

RAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes.

RAS Genes. The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes. ۱ RAS Genes The ras superfamily of genes encodes small GTP binding proteins that are responsible for the regulation of many cellular processes. Oncogenic ras genes in human cells include H ras, N ras,

More information

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture Neoplasia part I By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 2 nd Lecture Lecture outline Review of structure & function. Basic definitions. Classification of neoplasms. Morphologic features.

More information

Tumor microenvironment Interactions and Lung Cancer Invasiveness. Pulmonary Grand Rounds Philippe Montgrain, M.D.

Tumor microenvironment Interactions and Lung Cancer Invasiveness. Pulmonary Grand Rounds Philippe Montgrain, M.D. Tumor microenvironment Interactions and Lung Cancer Invasiveness Pulmonary Grand Rounds Philippe Montgrain, M.D. February 26, 2009 Objectives Review epithelial mesenchymal transition (EMT), and its implications

More information

Cancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage?

Cancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? Questions about cancer What is cancer? Cancer Gil McVean, Department of Statistics, Oxford What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? What are the steps in

More information

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,

More information

NEOPLASIA. 3. Which of the following tumour is benign a. Chondrosarcoma b. Osteochondroma c. Chondroblastoma d. Ewing s tumour e.

NEOPLASIA. 3. Which of the following tumour is benign a. Chondrosarcoma b. Osteochondroma c. Chondroblastoma d. Ewing s tumour e. NEOPLASIA 1. malignant neoplasms a. are independent of hormonal influence b. are always composed of homogenous cell lines c. arise from differentiated cells by a process of anaplasia d. display abnormal

More information

Ig light chain rearrangement: Rescue pathway

Ig light chain rearrangement: Rescue pathway B Cell Development Ig light chain rearrangement: Rescue pathway There is only a 1:3 chance of the join between the V and J region being in frame Vk Jk Ck Non-productive Rearrangement Light chain has a

More information

8: Lymphatic vessels and lymphoid tissue. nur

8: Lymphatic vessels and lymphoid tissue. nur 8: Lymphatic vessels and lymphoid tissue nur Lymphatic vascular system Functions return to the blood extracellular fluid (Lymph) from connective tissue spaces. ensures the return of water, electrolytes

More information

Chapter 2 (pages 22 33): Cells and Tissues of the Immune System. Prepared by Kristen Dazy, MD, Scripps Clinic Medical Group

Chapter 2 (pages 22 33): Cells and Tissues of the Immune System. Prepared by Kristen Dazy, MD, Scripps Clinic Medical Group Allergy and Immunology Review Corner: Cellular and Molecular Immunology, 8th Edition By Abul K. Abbas, MBBS; Andrew H. H. Lichtman, MD, PhD; and Shiv Pillai, MBBS, PhD. Chapter 2 (pages 22 33): Cells and

More information

Follicular Lymphoma. ced3 APOPTOSIS. *In the nematode Caenorhabditis elegans 131 of the organism's 1031 cells die during development.

Follicular Lymphoma. ced3 APOPTOSIS. *In the nematode Caenorhabditis elegans 131 of the organism's 1031 cells die during development. Harvard-MIT Division of Health Sciences and Technology HST.176: Cellular and Molecular Immunology Course Director: Dr. Shiv Pillai Follicular Lymphoma 1. Characterized by t(14:18) translocation 2. Ig heavy

More information

CRIPTO-1 A POSSIBLE NEW BIOMARKER IN GLIOBLASTOMA MULTIFORME PIA OLESEN, MD, PHD STUDENT

CRIPTO-1 A POSSIBLE NEW BIOMARKER IN GLIOBLASTOMA MULTIFORME PIA OLESEN, MD, PHD STUDENT CRIPTO-1 A POSSIBLE NEW BIOMARKER IN GLIOBLASTOMA MULTIFORME PIA OLESEN, MD, PHD STUDENT Glioblastoma WHO Grade IV Glioma Heterogenic Undiffenrentiated phenotype 50% of all Gliomas Around 600 patients

More information

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th

More information

OMICS Journals are welcoming Submissions

OMICS Journals are welcoming Submissions OMICS Journals are welcoming Submissions OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible

More information

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr. BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:

More information

Angiogenesis in Human Development. Vascular Development

Angiogenesis in Human Development. Vascular Development Angiogenesis in Human Development Jan Kitajewski ICRC 217B, ph 851-4688, email: jkk9 BACKGROUND READING: Vascular Development Signaling Vascular Morphogenesis and Maintenance Douglas Hanahan. Science 277:

More information

EGFR: fundamenteel en klinisch

EGFR: fundamenteel en klinisch EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation

More information

Cancer and Oncogenes Bioscience in the 21 st Century. Linda Lowe-Krentz

Cancer and Oncogenes Bioscience in the 21 st Century. Linda Lowe-Krentz Cancer and Oncogenes Bioscience in the 21 st Century Linda Lowe-Krentz December 1, 2010 Just a Few Numbers Becoming Cancer Genetic Defects Drugs Our friends and family 25 More mutations as 20 you get older

More information

A. Incorrect! It s not correct. Synergism of cytokines refers to two or more cytokines acting together.

A. Incorrect! It s not correct. Synergism of cytokines refers to two or more cytokines acting together. Immunology - Problem Drill 11: Cytokine and Cytokine Receptors Question No. 1 of 10 1. A single cytokine can act on several different cell types, which is known as. Question #1 (A) Synergism (B) Pleiotropism

More information

The Lymphatic System and Body Defenses

The Lymphatic System and Body Defenses PowerPoint Lecture Slide Presentation by Patty Bostwick-Taylor, Florence-Darlington Technical College The Lymphatic System and Body Defenses 12PART B Adaptive Defense System: Third Line of Defense Immune

More information

For personal use only

For personal use only ASX and Media release 6 April 211 Circadian s Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer Data demonstrates efficacy of with other therapeutic agents in mouse models of lung,

More information

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Neoplasia Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Considerations Overview: Neoplasia uncontrolled,

More information

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis. Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)

More information

Genetics and Cancer Ch 20

Genetics and Cancer Ch 20 Genetics and Cancer Ch 20 Cancer is genetic Hereditary cancers Predisposition genes Ex. some forms of colon cancer Sporadic cancers ~90% of cancers Descendants of cancerous cells all cancerous (clonal)

More information

The recruitment of leukocytes and plasma proteins from the blood to sites of infection and tissue injury is called inflammation

The recruitment of leukocytes and plasma proteins from the blood to sites of infection and tissue injury is called inflammation The migration of a particular type of leukocyte into a restricted type of tissue, or a tissue with an ongoing infection or injury, is often called leukocyte homing, and the general process of leukocyte

More information

Lymphoid Organs. Dr. Sami Zaqout. Dr. Sami Zaqout IUG Faculty of Medicine

Lymphoid Organs. Dr. Sami Zaqout. Dr. Sami Zaqout IUG Faculty of Medicine Lymphoid Organs Dr. Sami Zaqout Cells of the Immune System Lymphocytes Plasma cells Mast cells Neutrophils Eosinophils Cells of the mononuclear phagocyte system Distribution of cells of the immune system

More information

Tumor Associated Macrophages as a Novel Target for Cancer Therapy

Tumor Associated Macrophages as a Novel Target for Cancer Therapy Tumor mass Tumor Associated Macrophage Tumor Associated Macrophages as a Novel Target for Cancer Therapy This booklet contains forward-looking statements that are based on Amgen s current expectations

More information

Overview of the Lymphoid System

Overview of the Lymphoid System Overview of the Lymphoid System The Lymphoid System Protects us against disease Lymphoid system cells respond to Environmental pathogens Toxins Abnormal body cells, such as cancers Overview of the Lymphoid

More information

Flow Cytometry. Hanan Jafar (2017)

Flow Cytometry. Hanan Jafar (2017) 1 Flow Cytometry Flow cytometry is a popular laser-based technology to analyze the characteristics of cells or particles. It is predominantly used to measure fluorescence intensity produced by fluorescent-labeled

More information

Neoplasia 2018 lecture 11. Dr H Awad FRCPath

Neoplasia 2018 lecture 11. Dr H Awad FRCPath Neoplasia 2018 lecture 11 Dr H Awad FRCPath Clinical aspects of neoplasia Tumors affect patients by: 1. their location 2. hormonal secretions 3. paraneoplastic syndromes 4. cachexia Tumor location Even

More information

Healing & Repair. Tissue Regeneration

Healing & Repair. Tissue Regeneration Healing & Repair Dr. Srikumar Chakravarthi Repair & Healing: Are they same? Repair :Regeneration of injured cells by cells of same type, as with regeneration of skin/oral mucosa (requires basement membrane)

More information

Oncolytic Virotherapy: Targeting Cancer Stem Cells

Oncolytic Virotherapy: Targeting Cancer Stem Cells Oncolytic Virotherapy: Targeting Cancer Stem Cells Cancer Stem Cells (CSCs) or Cancer Initiating Cells (CICs) A consensus of five defining criteria has been established to affirm the existence of CICs:

More information

Effect of a nutrient mixture on the localization of extracellular matrix proteins in HeLa human cervical cancer xenografts in female nude mice

Effect of a nutrient mixture on the localization of extracellular matrix proteins in HeLa human cervical cancer xenografts in female nude mice Effect of a nutrient mixture on the localization of extracellular matrix proteins in HeLa human cervical cancer xenografts in female nude mice Publication from the Dr. Rath Research Institute Experimental

More information

Development of Next-generation Therapeutic

Development of Next-generation Therapeutic 2015 World Biologics Korea Development of Next-generation Therapeutic Antibodies for Treating Ovarian Cancer (Therapeutic Targeting of Tetraspanin8 in Epithelial Ovarian Cancer Invasion and Metastasis)

More information

Supplementary Materials. for Garmy-Susini, et al, Integrin 4 1 signaling is required for lymphangiogenesis and tumor metastasis

Supplementary Materials. for Garmy-Susini, et al, Integrin 4 1 signaling is required for lymphangiogenesis and tumor metastasis Supplementary Materials for Garmy-Susini, et al, Integrin 4 1 signaling is required for lymphangiogenesis and tumor metastasis 1 Supplementary Figure Legends Supplementary Figure 1: Integrin expression

More information

Prepared by: Dr.Mansour Al-Yazji

Prepared by: Dr.Mansour Al-Yazji C L L CLL Prepared by: Abd El-Hakeem Abd El-Rahman Abu Naser Ahmed Khamis Abu Warda Ahmed Mohammed Abu Ghaben Bassel Ziad Abu Warda Nedal Mostafa El-Nahhal Dr.Mansour Al-Yazji LEUKEMIA Leukemia is a form

More information

Chapter 9, Part 1: Biology of Cancer and Tumor Spread

Chapter 9, Part 1: Biology of Cancer and Tumor Spread PATHOPHYSIOLOGY Name Chapter 9, Part 1: Biology of Cancer and Tumor Spread I. Cancer Characteristics and Terminology Neoplasm new growth, involves the overgrowth of tissue to form a neoplastic mass (tumor).

More information

Diabetes Mellitus and Breast Cancer

Diabetes Mellitus and Breast Cancer Masur K, Thévenod F, Zänker KS (eds): Diabetes and Cancer. Epidemiological Evidence and Molecular Links. Front Diabetes. Basel, Karger, 2008, vol 19, pp 97 113 Diabetes Mellitus and Breast Cancer Ido Wolf

More information

Supplementary Table 1. Genes analysed for expression by angiogenesis gene-array.

Supplementary Table 1. Genes analysed for expression by angiogenesis gene-array. Supplementary Table 1. Genes analysed for expression by angiogenesis gene-array. Gene symbol Gene name TaqMan Assay ID UniGene ID 18S rrna 18S ribosomal RNA Hs99999901_s1 Actb actin, beta Mm00607939_s1

More information

The cardiovascular system

The cardiovascular system The cardiovascular system Components of the Cardiovascular system Heart Vessels: Arteries Capillaries Veins Functions of CVS: Transportation system where blood is the transporting vehicle Carries oxygen,

More information

CODING TUMOUR MORPHOLOGY. Otto Visser

CODING TUMOUR MORPHOLOGY. Otto Visser CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show

More information

Insulin Resistance. Biol 405 Molecular Medicine

Insulin Resistance. Biol 405 Molecular Medicine Insulin Resistance Biol 405 Molecular Medicine Insulin resistance: a subnormal biological response to insulin. Defects of either insulin secretion or insulin action can cause diabetes mellitus. Insulin-dependent

More information

Cancer arises from the mutation of a normal gene. A factor which brings about a mutation is called a mutagen.

Cancer arises from the mutation of a normal gene. A factor which brings about a mutation is called a mutagen. Cancer Single cells divide by mitosis to form many cells. This cells undergo physical and chemical changes in order to perform specific functions. (we say the cells have Differentiated) in this way we

More information

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management. Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician

More information